Canine Cancer Diagnostics
CADET™ BRAF and CADET™ BRAF-PLUS
Early and accurate detection of canine bladder and prostate cancer.
CADET™ BRAF
Accurate, affordable, and convenient
CADET™ BRAF evaluates canine urine samples for the presence of cells containing a mutation for canine bladder/prostate cancer (TCC/UC). This cutting-edge technology is accurate, affordable, and convenient for both veterinarian and pet owner.
Highly sensitive and accurate for early diagnosis of TCC/UC
Designed to monitor the BRAF mutation in canine TCC/UC cases during the course of treatment, for therapeutic response and relapse. CADET BRAF testing can be used for both the rapid, non-invasive assessment of dogs displaying clinical signs consistent with TCC/UC, and for confirmed cases undergoing treatment.
How CADET BRAF is used in a clinical setting
CADET BRAF evaluates free-catch urine samples from dogs for the presence of cells harboring the BRAF mutation or specific copy number variations associated with TCC/UC. The assays identify 95% of TCC/UC cases. The extremely low limit of detection of 10 mutation-bearing cells in a urine sample allows early diagnosis of a developing TCC/UC, often several months before any advanced clinical signs associated with the cancer become evident.
CADET™ BRAF-PLUS
CADET BRAF-PLUS provides further evaluation of dogs that present with clinical signs consistent with TCC/UC, but for which no BRAF mutation is detected. Our comprehensive analysis of thousands of clinical specimens has shown that CADET BRAF-PLUS detects more than two-thirds of the TCC/UC cases that are not identified by CADET BRAF.
Webinar: Using Molecular Diagnostics to Detect Canine Bladder and Prostate Cancer
In this one-hour webinar with Dr. Sue Ettinger, DVM, DACVIM (Oncology), you will learn about detecting both prostate and bladder cancer in canines utilizing the CADET™ BRAF urine test. This test facilitates early diagnosis in clinical cases with recurrent, complicated, or antibiotic-resistant urinary tract infections presenting with hematuria without ultrasonographic evidence of a bladder mass. Dr. Sue Ettinger will share how this test simplifies diagnosing these rare cancers to achieve better health outcomes.
Clinical indications for usage of CADET BRAF and
CADET BRAF-PLUS
Clinical cases presenting with hematuria, stranguria, and/or urinary incontinence, with diagnostic imaging evidence of a mass in the bladder.
Confirmation of the TCC/UC diagnosis of a bladder mass from a stained cytology slide following ultrasonography and cytological examination of a fine-needle aspirate from tumor-bearing cells.
During chemotherapy, to monitor treatment success by decreased levels of BRAF mutation detection, or to monitor cancer relapse by recurrence of BRAF mutation tumor-bearing cells.
Early detection in high-risk dog breeds such as terriers, Shetland sheepdogs, Australian shepherds, cattle dogs, beagles, and border collies that are ≥6 years of age.
Early diagnosis in clinical cases with recurrent, complicated, or antibiotic-resistant urinary tract infections presenting with hematuria without ultrasonographic evidence of a bladder mass.
Antech™ Support
- Daily 6:00 a.m. to 5:00 p.m. MT
- Emergency support after hours